Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm?-Reference-Cited by-同舟云学术

Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm?

Published:2021-12 Issue:6 Volume:4 Page:1006-1010
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Pederzoli Filippo,Bandini Marco,Marandino Laura,Raggi Daniele,Giannatempo Patrizia,Salonia Andrea,Gallina Andrea,Briganti Alberto,Montorsi Francesco,Necchi Andrea

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference29 articles.

1. Can biomarkers guide the use of neoadjuvant chemotherapy in T2 bladder cancer?;Grossman;Eur Urol Oncol,2019

2. How to improve patient selection for neoadjuvant chemotherapy in bladder cancer patients candidate for radical cystectomy and pelvic lymph node dissection;Zamboni;World J Urol,2020

3. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy;Culp;J Urol,2014

4. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides;Reardon;Eur Urol,2015

5. Effectiveness of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the current real world setting in the USA;Hanna;Eur Urol Oncol,2018

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances of Neoadjuvant Immunotherapy for Urothelial Bladder Cancer;Annals of Surgical Oncology;2024-07-12

2. Pembrolizumab;Reactions Weekly;2022-08-20

3. Advances in Diagnosis and Therapy for Bladder Cancer;Cancers;2022-06-29

4. Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints;Urologic Oncology: Seminars and Original Investigations;2022-02

5. Detailed bladder cancer immunoprofiling reveals new clues for immunotherapeutic strategies;Clinical & Translational Immunology;2022-01